A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required ...

While GLP-1 therapies like Ozempic gain traction, personalized peptide therapies are supporting long-term health goals ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Previous studies have found that SGLT2 inhibitors appear to lower HbA1c less in patients with worse kidney function.” “GLP-1 agonists appear to be less affected by this interaction,” he added.